Moderna's Melanoma Data Face Their Toughest Test: The Balance Sheet

BMO and UBS have pushed back against the market's downbeat reading of Moderna's personalised cancer vaccine results, arguing that the share-price slide reflects inflated expectations rather than weak science. Yet even the bulls concede that a working drug is not the same thing as a commercial winner — and the gap between the two is where the real investment debate now sits.

The data in question, released yesterday, come from the Phase 3 INTerpath-001 trial. Intismeran autogene combined with Keytruda cut the relative risk of recurrence or death by 42% versus Keytruda alone, and reduced the risk of distant metastasis or death by 38%. The study enrolled 1,137 patients with high-risk melanoma that had been fully removed surgically, meaning the vaccine's job is to stop the disease coming back. It is manufactured to match each patient's individual tumour mutations.

At two years, 82.2% of patients on the combination were recurrence-free and alive, against 70.0% on Keytruda alone, with a median follow-up of 24.6 months. That is a genuine clinical benefit on the endpoint studied. Overall survival data, however, are not yet mature — a limitation independent experts stress, since fewer events on a combined endpoint do not prove a survival advantage. The trial continues, and no new safety signals were reported.

Two Yards of Tape, One Share Price

BMO frames the violent market reaction as a correction of overblown expectations, while UBS calls the data strong across the board and sees the outlook for further studies in kidney and bladder cancer strengthened. Neither view amounts to evidence of a clinical failure — nor does either establish what revenue Moderna can actually generate from the treatment. Valuation depends on more than the readout: how long the benefit lasts, and whether an individually produced therapy can be delivered in practice.

That delivery question is a commercial hurdle in its own right. Tailored manufacturing currently takes about six weeks, a timeframe Merck CEO Robert Davis expects to shorten. As the BBC reported, any use in Britain's NHS would hinge on the cost of individual tumour analysis and vaccine production, with experts pointing to the required cost-benefit review. Clinical efficacy and economic viability, in other words, have to be judged on separate ledgers.

From Evidence to Regulators

Moderna and Merck said yesterday, according to Reuters, that they are in dialogue with regulatory authorities. That describes a next step, not a decision — a distinction that matters for anyone weighing the equity. The comparison underpinning the results is the combination against Keytruda alone, so the findings describe the added benefit within that specific treatment comparison. They should not be stretched into a general promise of protection, nor mistaken for an approval already granted.

The stock's 579% gain since the start of the year shows how far Moderna's valuation has already travelled. It does not substitute for a word from the regulators. The full presentation at the ESMO congress in Madrid is scheduled for 24 October, where the long-term benefit and the open manufacturing questions will draw the closest scrutiny.

Moderna is also testing the combination in lung, bladder and kidney cancer. A win in melanoma cannot be treated as a confirmed result in those running studies. The science, for now, is proven; the commercial scale of it is not.